Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT00321620
First received: May 2, 2006
Last updated: February 4, 2014
Last verified: February 2014
Results First Received: December 10, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Supportive Care
Condition: Bone Metastases
Interventions: Drug: zoledronic acid
Biological: denosumab

  Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Zoledronic Acid Zoledronic acid 4 mg by intravenous injection with a subcutaneous denosumab placebo once every 4 weeks
Denosumab Denosumab 120 mg subcutaneously with an intravenous zoledronic acid placebo once every 4 weeks
Total Total of all reporting groups

Baseline Measures
    Zoledronic Acid     Denosumab     Total  
Number of Participants  
[units: participants]
  951     950     1901  
Age  
[units: Years]
Mean ± Standard Deviation
  71.0  ± 8.4     70.5  ± 8.7     70.8  ± 8.6  
Gender  
[units: Participants]
     
Female     0     0     0  
Male     951     950     1901  
Race/Ethnicity, Customized  
[units: Participants]
     
White or Caucasian     810     829     1639  
Black or African American     35     38     73  
Hispanic or Latino     57     45     102  
Asian     26     22     48  
Native Hawaiian or Other Pacific Islander     1     1     2  
Other     22     15     37  
Prostate-Specific Antigen (PSA) Stratification Factor  
[units: Participants]
     
PSA level < 10 ng/mL     145     145     290  
PSA level ≥ 10 ng/mL     806     805     1611  
Previous Skeletal-Related Event (SRE) Stratification Factor  
[units: Participants]
     
Yes     231     232     463  
No     720     718     1438  
Current Prostate Cancer Chemotherapy Stratification Factor [1]
[units: Participants]
     
Yes     132     132     264  
No     819     818     1637  
[1] Defined as within 6 weeks before randomization



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Time to the First On-Study SRE (Non-inferiority)   [ Time Frame: Up to 40.5 months ]

2.  Secondary:   Time to the First On-Study SRE (Superiority)   [ Time Frame: Up to 40.5 months ]

3.  Secondary:   Time to the First-And-Subsequent On-Study SRE   [ Time Frame: Up to 40.5 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Study Director
Organization: Amgen Inc.
phone: 866-572-6436


No publications provided by Amgen

Publications automatically indexed to this study:


Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT00321620     History of Changes
Other Study ID Numbers: 20050103
Study First Received: May 2, 2006
Results First Received: December 10, 2010
Last Updated: February 4, 2014
Health Authority: Argentina: Ministry of Health
Australia: Therapeutic Goods Administration
Austria: Secretariat of Health
Belgium: Pharmaceutical Inspectorate
Brazil: Ministry of Health
Bulgaria: Ministry of Health
Canada: Health Products and Food Branch
Chile: Health Ministry
Czech Republic: State Institute for Drug Control
Denmark: Ministry of Health
Estonia: State Agency of Medicines
France: Ministry of Health
Germancy: Federal Institute for Drugs and Medical Devices
Greece: National Organization for Medicines
Guatemala: Ministry of Health
Hungary: Ministry of Health, Social and Family Affairs
Israel: Ministry of Health
Italy: Ministry of Health
Latvia: State Agency of Medicines
Lithuania: Ministry of Health
Mexico: Ministry of Health
Netherlands: Medicines Evaluation Board
Norway: Norwegian Medicines Agency
Panama: Ministry of Health, Peru: Ministry of Health
Poland: Drug Institut
Portugal: National Institute of Pharmacy and Medicines
Russia: Ministry of Health
Slovakia: Ministry of Health
South Africa: Department of Health
Spain: Spanish Drug Agency
Sweden: Medical Products Agency
Switzerland: Agency for Therapeutic Products
Turkey: Ministry of Health
Ukraine: Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration
Romania: Ministry of Health and the Family